VivoSeq
Oncology

Recurrent Cancer

0

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Recurrent Cancer is an early-stage landscape with 0 programs across 4 companies. The most active players are Gynecologic Oncology Group, Eli Lilly, Eastern Cooperative Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

73/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalE

Eastern Cooperative Oncology Group

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed11 · 69%
Terminated3 · 19%
Unknown status1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

16 trials

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Completed·National Cancer Institute (NCI)·Phase 1·NCT00019110
Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus
Completed·GGynecologic Oncology Group·Phase 3·NCT00003128·166 enrolled
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix
Completed·GGynecologic Oncology Group·Phase 2·NCT00087113
A Study of Pemetrexed in Children With Recurrent Cancer
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00520936·72 enrolled
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Completed·National Cancer Institute (NCI)·Phase 2·NCT00031993·51 enrolled
Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003017
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
Completed·UUniversity of Chicago·Phase 1·NCT00002939·21 enrolled
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Completed·National Cancer Institute (NCI)·Phase 2·NCT00025233·50 enrolled
Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung
Completed·UUniversity of New Mexico·N/A·NCT00277082·24 enrolled
DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT00004866
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00002506
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
Terminated·GGynecologic Oncology Group·Phase 2·NCT00006482
Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Terminated·GGynecologic Oncology Group·Phase 2·NCT00006224
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
Terminated·SWOG Cancer Research Network·Phase 2·NCT00022633·65 enrolled
Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
Withdrawn·UUniversity of Alabama at Birmingham·Phase 1·NCT00017537
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)